Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
It is demonstrated that MPL mutations outside exon 10 are uncommon in platelet cDNA and 4 different exon10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF are identified. Expand
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
- T. Barbui, G. Barosi, +18 authors A. Tefferi
- Journal of clinical oncology : official journal…
- 20 February 2011
We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition,… Expand
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of…
- H. Hasselbalch
- 5 April 2012
A link between chronic inflammation, atherosclerosis, and second cancer in MPNs favors early intervention at the time of diagnosis (statins and interferon-α2), the aims being to dampen chronic inflammation and clonal evolution and thereby also diminish concurrent disease-mediated Chronic inflammation and its consequences. Expand
Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura
- P. Brændstrup, O. Bjerrum, +11 authors H. Hasselbalch
- American journal of hematology
- 1 April 2005
It is concluded that rituximab may be a useful alternative therapy in patients with severe and symptomatic ITP refractory to conventional treatment. Expand
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- J. Grinfeld, J. Nangalia, +24 authors P. Campbell
- The New England journal of medicine
- 10 October 2018
Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms and may support the treatment of patients with myelofibrosis. Expand
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area
- M. Jensen, P. de Nully Brown, O. Nielsen, H. Hasselbalch
- European journal of haematology
- 1 August 2000
This study provides population‐based data suggesting the benefit of treatment with low‐dose ASA in a non‐selected population of patients with ET. Expand
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Patients positive for V617F had higher neutrophil and white cell counts and poorer overall survival, even after correction for confounding factors, but other diagnostic features were comparable between the 2 groups. Expand
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
Clinicohematologic, molecular, and histologic response categories were selected to develop a definition of response to treatment in polycythemia vera and essential thrombocythemia (ET) to help standardize the design and reporting of clinical studies. Expand
Activated Platelets Enhance IL-10 Secretion and Reduce TNF-α Secretion by Monocytes
- S. Gudbrandsdottir, H. Hasselbalch, C. Nielsen
- Chemistry, Medicine
- The Journal of Immunology
- 15 October 2013
It is suggested that activated platelets have anti-inflammatory properties related to the interaction between CD40L and CD40, and exert a hitherto undescribed immunoregulatory action by enhancing IL-10 production and inhibiting TNF-α production by monocytes. Expand